Table 1.
Demographic and Clinical Characteristics of Participants at Enrollment, and Drug-Resistance Status Based on Phenotypic Drug-Susceptibility Testing.
| Characteristic | Case-Detection Group* | Drug-Resistance-Risk Group† | All Participants |
|---|---|---|---|
| Demographic and clinical characteristics‡ | |||
| Enrolled in China — no./total no. (%) | 86/111 (77) | 196/290 (68) | 282/401 (70) |
| Enrolled in South Korea — no./total no. (%) | 25/111 (23) | 94/290 (32) | 119/401 (30) |
| Male sex — no./total no. (%) | 72/111 (65) | 230/290 (79) | 302/401 (75) |
| Median age (range) — yr | 48 (21–82) | 47 (18–85) | 47 (18–85) |
| Previous tuberculosis — no./total no. (%) | 0/111 (0) | 184/290 (63) | 184/401 (46) |
| Receiving tuberculosis treatment at enrollment — no./total no. (%) | 96/111 (86) | 285/290 (98) | 381/401 (95) |
| All study tests performed from one sputum specimen — no./total no. (%) | 72/111 (65) | 228/290 (79) | 300/401 (75) |
| Results of testing for Mycobacterium tuberculosis — no./total no. (%) | |||
| Study culture positive | 99/111 (89) | 223/290 (77) | 322/401 (80) |
| Smear microscopy positive for acid-fast bacilli | 67/111 (60) | 196/290 (68) | 263/401 (66) |
| Smear microscopy negative for acid-fast bacilli | 32/111 (29) | 27/290 (9) | 59/401 (15) |
| Study culture negative | 12/111 (11) | 67/290 (23) | 79/401 (20) |
| Drug-resistance status — no./total no. (%)§ | |||
| Isoniazid resistance only | 13/98 (13) | 14/210 (7) | 27/308 (9) |
| Rifampin resistance only | 0 | 2/210 (1) | 2/308 (0.6) |
| Fluoroquinolone resistance only | 2/98 (2) | 4/210 (2) | 6/308 (2) |
| Aminoglycoside resistance only | 1/98 (1) | 1/210 (0.5) | 2/308 (0.6) |
| Multidrug resistance only | 2/98 (2) | 53/210 (25) | 55/308 (18) |
| Multidrug resistance with fluoroquinolone resistance, aminoglycoside susceptibility | 0 | 46/210 (22) | 46/308 (15) |
| Multidrug resistance with aminoglycoside resistance, fluoroquinolone susceptibility | 1/98 (1) | 7/210 (3) | 8/308 (2.5) |
| Extensively drug resistant | 0 | 39/210 (19) | 39/308 (13) |
| Other polyresistance | 2/98 (2) | 7/210 (3) | 9/308 (3) |
| No resistance to isoniazid, rifampin, fluoroquinolones, or aminoglycosides | 77/98 (79) | 37/210 (18) | 114/308 (37) |
Participants in this group had suspected or confirmed new pulmonary tuberculosis and had received antituberculosis drugs for less than 3 days.
Participants in this group either had confirmed pulmonary tuberculosis with documented rifampin resistance and had received antituberculosis drugs for 31 days or less or had a history of tuberculosis plus ongoing signs or symptoms of pulmonary tuberculosis and suspected drug resistance.
Demographic and clinical characteristics are reported for the 401 study-eligible participants.
Drug-resistance status is reported for the 308 participants in the main analysis population for drug-susceptibility testing.